Catabasis Pharmaceuticals is a US-based biopharmaceutical company that focuses on developing and commercializing therapeutics. Its lead product candidate is edasalonexent, which is currently in Phase III clinical trial for the treatment of Duchenne muscular dystrophy. The company is also developing CAT-5571 for the treatment of cystic fibrosis and has research collaborations with the Jain Foundation and the Bill & Melinda Gates Medical Research Institute.